Company Profile
PharmaNutra S.p.A. specializes in the research, development and marketing of nutraceutical products. Also, the group develops an activity involving the manufacturing and sales of medical devices and pharmaceuticals. Net sales break down by family of products as follows:
- food supplements (92.7%): iron, folic acids, vitamins, omega 3 and microelement-based products sold under the Sideral®, Apportal®, Sidevit®, Cetilar® Nutrition, Ultramag®, Sidevit® B12 and other brands, intended for the treatment of anemia and food deficit, and the prevention of cardiovascular disorders. Additionally, PharmaNutra S.p.A. offers anti-inflammatory products for joint and musculoskeletal pain relief (Cetilar®);
- medical instruments and devices (5.2%);
- bioactive ingredients and pharmaceutical active ingredients (2.1%): for the pharmaceutical, agri-food and nutraceutical industries.
Its products are marketed through direct sales (58.1% of net sales), partner distributors (38.6%) and other (5.2%).
Net sales are distributed geographically as follows: Italy (62.6%), Europe (18%), Middle East (10.6%), Far East (3.6%), South America (2.2%), North America (0.7%) and other (2.3%).
- food supplements (92.7%): iron, folic acids, vitamins, omega 3 and microelement-based products sold under the Sideral®, Apportal®, Sidevit®, Cetilar® Nutrition, Ultramag®, Sidevit® B12 and other brands, intended for the treatment of anemia and food deficit, and the prevention of cardiovascular disorders. Additionally, PharmaNutra S.p.A. offers anti-inflammatory products for joint and musculoskeletal pain relief (Cetilar®);
- medical instruments and devices (5.2%);
- bioactive ingredients and pharmaceutical active ingredients (2.1%): for the pharmaceutical, agri-food and nutraceutical industries.
Its products are marketed through direct sales (58.1% of net sales), partner distributors (38.6%) and other (5.2%).
Net sales are distributed geographically as follows: Italy (62.6%), Europe (18%), Middle East (10.6%), Far East (3.6%), South America (2.2%), North America (0.7%) and other (2.3%).
Source: Cofisem - Last Update: 2026-05-19
Key Executives
| Chairman and Chief Executive Officer | |
| Co-CEO | |
| Chief Operating Officer |
Source: Cofisem - Last Update: 2026-05-19
Key Figures
| Millenium | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net sales | 133,968 | 116,911 | 100,202 | 82,724 | 68,114 |
| Income from ordinary activities | 133,968 | 116,911 | 101,963 | 82,724 | 68,114 |
| Operating income | 30,312 | 27,374 | 23,360 | 23,040 | 18,691 |
| Cost of financial indebtedness net | 147 | 386 | 482 | -68 | -99 |
| Equity-accounted companies contribution to income | |||||
| Net profit from discontinued activities | |||||
| Net income | 19,917 | 16,551 | 12,832 | 15,048 | 13,771 |
| Net income (Group share) | 20,002 | 16,608 | 12,832 | 15,048 | 13,771 |
| Fiscal year end | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | IFRS | IFRS | IFRS | IFRS | IFRS |
Source: Cofisem - Last Update: 2026-05-19
Shareholder information
| Free float | |
| ALH S.r.l. | |
| RLH S.r.l. | |
| Beda S.r.l. | |
| Treasury shares | |
| Roberto Lacorte |
Source: Cofisem - Last Update: 2026-05-19
Address
PharmaNutra S.p.A.
Via Campodavela 1
IT-56122 Pisa
Italy
Phone number: +39 050 7846500
https://www.pharmanutra.it/it/
Source: Cofisem - Last Update: 2026-05-19
Contact
Francesco Sarti
Phone number: +390507846500
f.sarti@pharmanutra.it
Phone number: +390507846500
f.sarti@pharmanutra.it
Source: PharmaNutra S.p.A. - Last Update: 2026-05-19
Please contact MyQuestion.Italy@euronext.com for Company Profile support.